ESR1 and breast carcinoma: In the MA12 trial comprising 328 premenopausal patients with ER+ primary breast cancer of all histological subtypes, non-silent ERBB2 mutations occurred in 5.2% of patients (N = 17) and were adversely prognostic of OS (p = 0.0114) [22].